報價延遲最少15分鐘:2026/03/26 22:47 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.69 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.09/-0.28
|
|
企業價值
1.53B
|
| 資產負債 |
|
每股賬面淨值
1.70
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
263.50M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World. |
